Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00798603
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substan... Read More
Gender:
ALL
Ages:
Between 70 years and 120 years
Trial Updated:
12/01/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +216 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00032032
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +50 locations
Conditions: Lung Cancer
Register for Updates
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
NCT01167192
Terminated
The purpose of this study is to determine whether platinum-based chemotherapy (either cisplatin or carboplatin), when given with radiation therapy prior to surgery, is effective in improving response to treatment in triple negative breast cancer patients. This treatment is being studied in this type of breast cancer because it does not respond well to commonly used treatments such as tamoxifen or herceptin.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/09/2016
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Breast Neoplasms
Register for Updates
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT00811993
Terminated
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are eligible for the study: untreated, treated and requiring further treatment, or treated and failed and for whom adding R1507 represents a suitable treatment for their disease. All regimens will first t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Tucson, Arizona +7 locations
Conditions: Neoplasms
Register for Updates
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT00974584
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Buffalo, New York +2 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
NCT01301716
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Los Angeles, California +4 locations
Conditions: Solid Cancers
Register for Updates
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
NCT01366131
Completed
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with histologically or cytologically documented inoperable, locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Birmingham, Alabama +41 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02035345
Terminated
This is a research study to determine if administering carboplatin at a slower rate when re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity reaction will decrease the frequency and severity of future hypersensitivity reactions.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
Register for Updates
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
NCT00352690
Terminated
This study is intended to evaluate the role of paclitaxel poliglumex and carboplatin in the treatment of unresectable Stage III non-small cell lung cancer along with radiation therapy in a multi-institutional trial. Consolidation chemotherapy with paclitaxel poliglumex and carboplatin will follow the completion of chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2016
Locations: University of California, San Francisco, San Francisco, California +7 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Ixabepilone + Carboplatin Metastatic Breast Cancer
NCT01075100
Completed
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2016
Locations: Hematology Oncology Associates, Phoenix, Arizona +58 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
NCT01497470
Completed
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2016
Locations: Teva Investigational Site 002, Detroit, Michigan +3 locations
Conditions: Cancer
Register for Updates
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NCT00874848
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2016
Locations: Medical College of Georgia, Augusta, Georgia +13 locations
Conditions: NSCLC
Register for Updates